Release date: 12 July 2007
Promoter – Financial Intermediary
Global Health Care GroupLocation
Description
European R&D site(s) of the promoter.
Objectives
The project comprises the promoter’s ongoing R&D programme 2007-2009 and includes expenditures incurred in the promoter’s European facilities for internal personnel and other operating costs as well as expenses for clinical trials, cooperation, licences, patent registration and laboratory equipment.
Comments
This RDI project, encompassing leading R&D in biopharmaceutical and in medical devices aims at the development of innovative therapies and products targeting life-threatening diseases.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 150 million.
Total cost (Approximate amount)
EUR 415 million.
Environmental aspects
RDI activities will not materially change current RDI practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement.
Status
Signed - 28/08/2009
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).